Comparison · NCT03036150-f4111299
Dapagliflozin vs Placebo: Time to Death From Any Cause.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dapagliflozin vs Placebo: Time to Death From Any Cause. Trial comparisons, record NCT03036150-f4111299. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03036150-f4111299
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0469 | 0.0388 | 0.0567 | wilson | |
| Risk in group 2 | 0.0678 | 0.058 | 0.0793 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0209 | -0.0349 | -0.00702 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.692 | 0.541 | 0.885 | log | |
| Odds ratio, group 1 over group 2 | 0.677 | 0.521 | 0.878 | log | |
| Number needed to treat, for one fewer participant with the outcome on Dapagliflozin than on Placebo | 47.8 | 28.6 | 142 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dapagliflozin | Dapagliflozin 10 mg, given once daily per oral use | 101 | 2,152 | OG000 |
| Group 2 | Placebo | Placebo tablet to match dapagliflozin 10 mg, given once daily per oral use | 146 | 2,152 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Time to Death From Any Cause.
- Description
The proportional hazards Cox regression model takes into account the time to the event. Data is reported as the numbers of subjects with the event and the Hazard ratio is included in the Statistical Analysis section attached to the Outcome Measure data table.
- Time frame
- Up to 38.2 months
- Population
For the secondary endpoints the Full Analysis Set was used. This included all patients who were randomized to study treatment. Patients were analyzed according to their randomized treatment assignment.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease
- NCT number
- NCT03036150
- Phases
- PHASE3
- Conditions
- Chronic Kidney Disease
- Interventions
- Dapagliflozin, Placebo
- Lead sponsor
- AstraZeneca
- Results first posted
- 2021-07-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03036150?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03036150-f4111299